{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T06:59:12Z","timestamp":1780901952106,"version":"3.54.1"},"reference-count":141,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Inflammatory bowel diseases (IBD) including ulcerative colitis and Crohn\u2019s disease can be associated with other immune-mediated inflammatory diseases (IMIDs) and extraintestinal manifestations (EIM) including dermatological manifestations, ophthalmologic manifestations, musculoskeletal manifestations and neurological manifestations. The aim of this narrative review is to discuss the optimal management and treatment strategy of IBD with immune-mediated inflammatory disease and extraintestinal manifestations. Methods: This review is based on published studies searched in PubMed until 31 December 2025. Our search focused on systemic reviews, review articles, randomized trials, cohort studies, guidelines and case series. Results: In IBD, the presence of additional immune-mediated inflammatory diseases (IMIDs) should be considered a poor prognostic factor, prompting closer disease monitoring and earlier escalation to or optimization of advanced therapy. Therapeutic management requires careful consideration including a multidisciplinary approach and a selection of the most appropriate treatment option(s) based on the presence, severity of IBD and\/or IMIDs and\/or EIM. For patients with refractory disease affecting multiple organs, emerging strategies include dual biologic therapies. Conclusions: The optimal management of IBD with associated IMIDs\/EIM should be multidisciplinary in close cooperation among specialists to align treatment goals and management plans.<\/jats:p>","DOI":"10.3390\/jcm15124408","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T05:43:46Z","timestamp":1780897426000},"page":"4408","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["IBD and Immune-Mediated Inflammatory Diseases: What Is the Optimal Management?"],"prefix":"10.3390","volume":"15","author":[{"given":"Mohammad","family":"Alsaeid","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, McGill University, Montreal, QC H4A 3J1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamah","family":"Abu Hawi","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, McGill University, Montreal, QC H4A 3J1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2610-1910","authenticated-orcid":false,"given":"Talat","family":"Bessissow","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, McGill University, Montreal, QC H4A 3J1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3948-6488","authenticated-orcid":false,"given":"Peter L.","family":"Lakatos","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, McGill University, Montreal, QC H4A 3J1, Canada"},{"name":"Department of Internal Medicine and Oncology, Semmelweis University, 1083 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/15476910802129604","article-title":"Immune-Mediated Diseases II Congress: Summary","volume":"5","author":"Shurin","year":"2008","journal-title":"J. Immunotoxicol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/joim.12395","article-title":"Human autoimmune diseases: A comprehensive update","volume":"278","author":"Wang","year":"2015","journal-title":"J. Intern. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"10731","DOI":"10.1038\/s41598-020-67710-2","article-title":"Impact of immune-mediated diseases in inflammatory bowel disease and implications in therapeutic approach","volume":"10","author":"Pascual","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/ibd\/izaa167","article-title":"Systematic Review with Meta-analysis: The Impact of Co-occurring Immune-mediated Inflammatory Diseases on the Disease Course of Inflammatory Bowel Diseases","volume":"27","author":"Attauabi","year":"2021","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_5","first-page":"438","article-title":"Management of Concomitant Inflammatory Bowel Disease or Uveitis in Patients with Psoriatic Arthritis: An Updated Review Informing the 2021 GRAPPA Treatment Recommendations","volume":"50","author":"Jadon","year":"2022","journal-title":"J. Rheumatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1080\/1744666X.2023.2249235","article-title":"Managing psoriatic arthritis in different clinical scenarios","volume":"19","author":"Queiro","year":"2023","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S2468-1253(21)00297-1","article-title":"Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: The EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases","volume":"7","author":"Guillo","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1111\/j.1572-0241.2007.01215.x","article-title":"Clustering of Inflammatory Bowel Disease with Immune Mediated Diseases Among Members of a Northern California-Managed Care Organization","volume":"102","author":"Weng","year":"2007","journal-title":"Am. J. Gastroenterol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.3748\/wjg.v9.i10.2300","article-title":"Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: Results of a 25-year follow-up study","volume":"9","author":"Lakatos","year":"2003","journal-title":"World J. Gastroenterol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.14309\/ajg.0000000000003465","article-title":"ACG Clinical Guideline: Management of Crohn\u2019s Disease in Adults","volume":"120","author":"Lichtenstein","year":"2025","journal-title":"Am. J. Gastroenterol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/ajg.2011.58","article-title":"An Evidence-Based Systematic Review on Medical Therapies for Inflammatory Bowel Disease","volume":"106","author":"Talley","year":"2011","journal-title":"Am. J. Gastroenterol."},{"key":"ref_12","first-page":"CD001461","article-title":"Azathioprine for treating rheumatoid arthritis","volume":"2000","author":"Spooner","year":"2000","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.14309\/ajg.0000000000003463","article-title":"ACG Clinical Guideline Update: Ulcerative Colitis in Adults","volume":"120","author":"Rubin","year":"2025","journal-title":"Am. J. Gastroenterol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1053\/j.gastro.2025.09.038","article-title":"AGA Living Clinical Practice Guideline on the Pharmacologic Management of Moderate-to-Severe Crohn\u2019s Disease","volume":"169","author":"Scott","year":"2025","journal-title":"Gastroenterology"},{"key":"ref_15","first-page":"CD000957","article-title":"Methotrexate for treating rheumatoid arthritis","volume":"2014","author":"Siddhanamatha","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0140-6736(16)32127-4","article-title":"An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): A 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Warren","year":"2017","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s00403-024-03066-1","article-title":"Analysis of factors influencing target PASI responses and side effects of methotrexate monotherapy in plaque psoriasis: A multicenter study of 1521 patients","volume":"316","author":"Erduran","year":"2024","journal-title":"Arch. Dermatol. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3899\/jrheum.150614","article-title":"Methotrexate Efficacy in the Tight Control in Psoriatic Arthritis Study","volume":"43","author":"Coates","year":"2016","journal-title":"J. Rheumatol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Zhang, M., Li, M., Ou, Y., Huang, Q., Leng, M., Yang, X., and Yang, T. (2025). Infliximab for patients with moderate to severely active ulcerative colitis: An updated meta-analysis of randomized controlled trials. BMC Gastroenterol., 25.","DOI":"10.1186\/s12876-025-04065-w"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: The ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"key":"ref_22","first-page":"CD005468","article-title":"TNF-alpha inhibitors for ankylosing spondylitis","volume":"2015","author":"Maxwell","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_23","first-page":"427","article-title":"Treatment options for the comorbidity of multiple sclerosis with other chronic inflammatory diseases","volume":"122","author":"Bittner","year":"2025","journal-title":"Dtsch. \u00c4rzteblatt Int."},{"key":"ref_24","first-page":"CD003785","article-title":"Infliximab for the treatment of rheumatoid arthritis","volume":"2010","author":"Blumenauer","year":"2002","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/gut.2005.074815","article-title":"Infliximab for the treatment of pyoderma gangrenosum: A randomised, double blind, placebo controlled trial","volume":"55","author":"Brooklyn","year":"2006","journal-title":"Gut"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cgh.2016.06.025","article-title":"Systematic Review of Tumor Necrosis Factor Antagonists in Extraintestinal Manifestations in Inflammatory Bowel Disease","volume":"15","author":"Lara","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_27","first-page":"e15691","article-title":"Infliximab in hidradenitis suppurativa: A systematic review and meta-analysis","volume":"35","author":"Shih","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab Induces and Maintains Clinical Remission in Patients with Moderate-to-Severe Ulcerative Colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_30","first-page":"CD005113","article-title":"Adalimumab for treating rheumatoid arthritis","volume":"2010","author":"Villanueva","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ophtha.2025.10.004","article-title":"Adalimumab versus Conventional Immunosuppression for Uveitis (ADVISE) Trial","volume":"133","author":"Jabs","year":"2026","journal-title":"Ophthalmology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/iwj.13067","article-title":"Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi-systematic review","volume":"16","author":"Fogh","year":"2019","journal-title":"Int. Wound J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e26190","DOI":"10.1097\/MD.0000000000026190","article-title":"Efficacy and safety of adalimumab in hidradenitis suppurativa: A systematic review and meta-analysis of randomized controlled trials","volume":"100","author":"Lu","year":"2021","journal-title":"Medicine"},{"key":"ref_34","first-page":"CD012893","article-title":"Certolizumab pegol for induction of remission in Crohn\u2019s disease","volume":"2019","author":"Yamazaki","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","article-title":"Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study","volume":"73","author":"Braun","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_36","first-page":"CD007649","article-title":"Certolizumab pegol (CDP870) for rheumatoid arthritis in adults","volume":"2017","author":"Burls","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1001\/jama.2025.4358","article-title":"Uveitis in Adults: A Review","volume":"334","author":"Maghsoudlou","year":"2025","journal-title":"JAMA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/art.40226","article-title":"Safety and Efficacy of Intravenous Golimumab in Patients with Active Psoriatic Arthritis: Results Through Week Twenty-Four of the GO-VIBRANT Study","volume":"69","author":"Kavanaugh","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.2024.20917","article-title":"Axial Spondyloarthritis: A Review","volume":"333","author":"Bittar","year":"2025","journal-title":"JAMA"},{"key":"ref_40","first-page":"CD008341","article-title":"Golimumab for rheumatoid arthritis","volume":"2010","author":"Singh","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.dld.2021.11.014","article-title":"Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn\u2019s disease\u2014A systematic review with meta-analysis","volume":"54","author":"Attauabi","year":"2022","journal-title":"Dig. Liver Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1111\/jgh.16612","article-title":"The impact of vedolizumab therapy on extraintestinal manifestations in patients with inflammatory bowel disease: A systematic review and meta-analysis","volume":"39","author":"Zheng","year":"2024","journal-title":"J. Gastro Hepatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_44","first-page":"CD007572","article-title":"Anti-IL-12\/23p40 antibodies for induction of remission in Crohn\u2019s disease","volume":"2025","author":"Hasskamp","year":"2025","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1016\/S0140-6736(18)30949-8","article-title":"Clinical management of psoriatic arthritis","volume":"391","author":"Coates","year":"2018","journal-title":"Lancet"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","article-title":"Risankizumab as induction therapy for Crohn\u2019s disease: Results from the phase 3 ADVANCE and MOTIVATE induction trials","volume":"399","author":"Panaccione","year":"2022","journal-title":"Lancet"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/jama.2024.12414","article-title":"Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials","volume":"332","author":"Louis","year":"2024","journal-title":"JAMA"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): Results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1093\/rheumatology\/keac607","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study","volume":"62","author":"Kristensen","year":"2023","journal-title":"Rheumatology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(25)00681-6","article-title":"Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn\u2019s disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials","volume":"406","author":"Panaccione","year":"2025","journal-title":"Lancet"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0140-6736(24)01927-5","article-title":"Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): Phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies","volume":"405","author":"Rubin","year":"2024","journal-title":"Lancet"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): A double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"388","author":"Dubinsky","year":"2023","journal-title":"New Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/S0140-6736(24)01762-8","article-title":"Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn\u2019s disease: A phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study","volume":"404","author":"Ferrante","year":"2024","journal-title":"Lancet"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/bjd.21743","article-title":"Efficacy and safety of mirikizumab in psoriasis: Results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1)","volume":"187","author":"Blauvelt","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1016\/S2665-9913(23)00120-0","article-title":"Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): A phase 3, multicentre, randomised, double-blind study","volume":"5","author":"Papp","year":"2023","journal-title":"Lancet Rheumatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"New Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): A phase 3b\/4, double-blind, head-to-head, randomised controlled trial","volume":"390","author":"Fleischmann","year":"2017","journal-title":"Lancet"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"New Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1136\/annrheumdis-2020-219601","article-title":"Tofacitinib for the treatment of ankylosing spondylitis: A phase III, randomised, double-blind, placebo-controlled study","volume":"80","author":"Deodhar","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.jaad.2020.02.044","article-title":"Joint American Academy of Dermatology\u2013National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies","volume":"82","author":"Menter","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: Results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib Induction and Maintenance Therapy for Crohn\u2019s Disease","volume":"388","author":"Loftus","year":"2023","journal-title":"New Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1002\/art.41384","article-title":"Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately-to-Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator\u2013Controlled Trial","volume":"72","author":"Takeuchi","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis","volume":"384","author":"McInnes","year":"2021","journal-title":"New Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): A multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial","volume":"394","author":"Song","year":"2019","journal-title":"Lancet"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S1474-4422(19)30239-X","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): A multicentre, randomised, 24-month, phase 3 trial","volume":"18","author":"Comi","year":"2019","journal-title":"Lancet Neurol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"New Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): Two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet"},{"key":"ref_70","first-page":"CD006097","article-title":"Natalizumab for induction of remission in Crohn\u2019s disease","volume":"2018","author":"Nelson","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S1474-4422(11)70149-1","article-title":"Natalizumab treatment for multiple sclerosis: Updated recommendations for patient selection and monitoring","volume":"10","author":"Kappos","year":"2011","journal-title":"Lancet Neurol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"New Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1007\/s12325-023-02568-0","article-title":"Safety of IL-23 p19 Inhibitors for the Treatment of Patients with Moderate-to-Severe Plaque Psoriasis: A Narrative Review","volume":"40","author":"Blauvelt","year":"2023","journal-title":"Adv. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/apt.16060","article-title":"Long-term safety of vedolizumab for inflammatory bowel disease","volume":"52","author":"Loftus","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1097\/MIB.0b013e318281f28f","article-title":"Safety of Thiopurine Therapy in Inflammatory Bowel Disease","volume":"19","author":"Chaparro","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/apt.16315","article-title":"Effectiveness and safety of methotrexate monotherapy in patients with Crohn\u2019s disease refractory to anti-TNF-\u03b1: Results from the ENEIDA registry","volume":"53","author":"Mesonero","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"17562848241272995","DOI":"10.1177\/17562848241272995","article-title":"Advanced combination therapy: Is it the best way to break the therapeutic ceiling?","volume":"17","author":"Wetwittayakhlang","year":"2024","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/ajg.2010.343","article-title":"Frequency and Risk Factors for Extraintestinal Manifestations in the Swiss Inflammatory Bowel Disease Cohort","volume":"106","author":"Vavricka","year":"2011","journal-title":"Am. J. Gastroenterol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/j.gastro.2005.06.021","article-title":"The Clustering of Other Chronic Inflammatory Diseases in Inflammatory Bowel Disease: A Population-Based Study","volume":"129","author":"Bernstein","year":"2005","journal-title":"Gastroenterology"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"7146","DOI":"10.1038\/ncomms8146","article-title":"Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1","volume":"6","author":"Cortes","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Australo-Anglo-American Spondyloarthritis Consortium (TASC), Wellcome Trust Case Control Consortium 2 (WTCCC2), Evans, D.M., Spencer, C.C., Pointon, J.J., Su, Z., Harvey, D., Kochan, G., Oppermann, U., and Dilthey, A. (2011). Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat. Genet., 43, 761\u2013767.","DOI":"10.1038\/ng0911-919a"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nrgastro.2014.142","article-title":"Fistulising disease\u2014a problem shared is a problem halved?","volume":"11","author":"Rogler","year":"2014","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"848","DOI":"10.3109\/00365521.2016.1140807","article-title":"Association of extraintestinal manifestations and anaemia with disease outcomes in patients with inflammatory bowel disease","volume":"51","author":"Vegh","year":"2016","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","article-title":"Primary sclerosing cholangitis \u2013 a comprehensive review","volume":"67","author":"Karlsen","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1136\/gutjnl-2018-317993","article-title":"British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis","volume":"68","author":"Chapman","year":"2019","journal-title":"Gut"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0002-9378(76)90154-X","article-title":"Rapid infusion of sodium bicarbonate and albumin into high-risk premature infants soon after birth: A controlled, prospective trial","volume":"124","author":"Bland","year":"1976","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1053\/j.gastro.2013.06.052","article-title":"Pathogenesis of Primary Sclerosing Cholangitis and Advances in Diagnosis and Management","volume":"145","author":"Eaton","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1053\/gast.1996.v110.pm8613055","article-title":"Primary sclerosing cholangitis is associated with nonsmoking: A case- control study","volume":"110","author":"Loftus","year":"1996","journal-title":"Gastroenterology"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities","volume":"80","author":"Elmets","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1001\/jamadermatol.2022.3682","article-title":"Association Between Inflammatory Bowel Disease and Both Psoriasis and Psoriatic Arthritis: A Bidirectional 2-Sample Mendelian Randomization Study","volume":"158","author":"Freuer","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1159\/000514030","article-title":"Incidence of Psoriasis in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Matched Cohort Study","volume":"237","author":"Moon","year":"2021","journal-title":"Dermatology"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1159\/000500116","article-title":"Psoriasis and Inflammatory Bowel Disease","volume":"37","author":"Cottone","year":"2019","journal-title":"Dig. Dis."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41575-023-00768-1","article-title":"IL-12 and IL-23 pathway inhibition in inflammatory bowel disease","volume":"20","author":"Verstockt","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.40726","article-title":"2018 American College of Rheumatology\/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis","volume":"71","author":"Singh","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/ard.2004.032268","article-title":"Infliximab improves signs and symptoms of psoriatic arthritis: Results of the IMPACT 2 trial","volume":"64","author":"Antoni","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): A double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"ref_97","first-page":"CD011535","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: A network meta-analysis","volume":"2025","author":"Sbidian","year":"2025","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s12876-020-01339-3","article-title":"The risk of rheumatoid arthritis among patients with inflammatory bowel disease: A systematic review and meta-analysis","volume":"20","author":"Chen","year":"2020","journal-title":"BMC Gastroenterol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor \u03b1 monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1002\/acr.24025","article-title":"2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Care Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/apt.15370","article-title":"Increased risk of developing Crohn\u2019s disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNF\u03b1 agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease","volume":"50","author":"Korzenik","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s00415-016-8340-8","article-title":"Multiple sclerosis and inflammatory bowel diseases: A systematic review and meta-analysis","volume":"264","author":"Kosmidou","year":"2016","journal-title":"J. Neurol."},{"key":"ref_104","first-page":"1135","article-title":"Milder multiple sclerosis course in patients with concomitant inflammatory bowel disease","volume":"20","author":"Salleron","year":"2013","journal-title":"Mult. Scler. J."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"New Engl. J. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1474-4422(19)30239-X","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): A multicentre, randomised, minimum 12-month, phase 3 trial","volume":"18","author":"Comi","year":"2019","journal-title":"Lancet Neurol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: A retrospective analysis of data from four clinical studies","volume":"16","author":"Ho","year":"2017","journal-title":"Lancet Neurol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0140-6736(24)02475-9","article-title":"Hidradenitis suppurativa","volume":"405","author":"Sabat","year":"2025","journal-title":"Lancet"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1001\/jama.2017.16691","article-title":"Hidradenitis Suppurativa","volume":"318","author":"Saunte","year":"2017","journal-title":"JAMA"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"New Engl. J. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaad.2019.02.068","article-title":"North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations","volume":"81","author":"Alikhan","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"103818","DOI":"10.1016\/j.autrev.2025.103818","article-title":"The role of interleukin inhibitors in the treatment of hidradenitis suppurativa; a systematic review of clinical trials","volume":"24","author":"Heidari","year":"2025","journal-title":"Autoimmun. Rev."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"103853","DOI":"10.1016\/j.autrev.2025.103853","article-title":"Clinical features, pathogenesis, and treatment of inflammatory bowel disease-associated spondyloarthritis","volume":"24","author":"Akiyama","year":"2025","journal-title":"Autoimmun. Rev."},{"key":"ref_114","first-page":"631","article-title":"The Prevalence and Incidence of Axial and Peripheral Spondyloarthritis in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis","volume":"11","author":"Karreman","year":"2016","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1080\/1744666X.2018.1513329","article-title":"Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases","volume":"14","author":"Felice","year":"2018","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo-controlled trial (ASSERT)","volume":"52","author":"Dijkmans","year":"2005","journal-title":"Arthritis Rheum."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1053\/j.gastro.2021.07.042","article-title":"Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management","volume":"161","author":"Rogler","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s12016-017-8617-4","article-title":"Skin Manifestations of Inflammatory Bowel Disease","volume":"53","author":"Greuter","year":"2017","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s12325-018-0678-0","article-title":"Adalimumab Reduces Extraintestinal Manifestations in Patients with Crohn\u2019s Disease: A Pooled Analysis of 11 Clinical Studies","volume":"35","author":"Louis","year":"2018","journal-title":"Adv. Ther."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/ibd\/izaf228","article-title":"Cutaneous Manifestations and Dermatologic Adverse Events in IBD: A Clinical Update","volume":"32","author":"Tsilimpotis","year":"2025","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ueg2.12094","article-title":"The impact of ustekinumab on extraintestinal manifestations of Crohn\u2019s disease: A post hoc analysis of the UNITI studies","volume":"9","author":"Narula","year":"2021","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/S2468-1253(22)00021-8","article-title":"Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: An International Organization for Study of Inflammatory Bowel Diseases consensus","volume":"7","author":"Ananthakrishnan","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2020.18936","article-title":"Management of Crohn Disease: A Review","volume":"325","author":"Cushing","year":"2021","journal-title":"JAMA"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/jama.2023.15389","article-title":"Ulcerative Colitis in Adults: A Review","volume":"330","author":"Gros","year":"2023","journal-title":"JAMA"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1093\/ibd\/izy174","article-title":"Pyoderma Gangrenosum: A Review for the Gastroenterologist","volume":"24","author":"Plumptre","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/apt.12431","article-title":"Systematic review: IBD-associated pyoderma gangrenosum in the biologic era, the response to therapy","volume":"38","author":"Agarwal","year":"2013","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.det.2023.12.002","article-title":"Treatment of Pyoderma Gangrenosum","volume":"42","author":"Tan","year":"2024","journal-title":"Dermatol. Clin."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.3748\/wjg.v23.i32.5836","article-title":"Ophthalmic manifestations in patients with inflammatory bowel disease: A review","volume":"23","author":"Troncoso","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"825","DOI":"10.3899\/jrheum.2023-0788","article-title":"Scleritis and Development of Immune-Mediated Disease: A Retrospective Chart Review","volume":"51","author":"Morrison","year":"2024","journal-title":"J. Rheumatol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/S0161-6420(93)31473-9","article-title":"An Analysis of Therapeutic Decision for Scleritis","volume":"100","author":"Jabbur","year":"1993","journal-title":"Ophthalmology"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1136\/bjophthalmol-2018-312767","article-title":"Long-term efficacy and tolerability of TNF\u03b1 inhibitors in the treatment of non-infectious ocular inflammation: An 8-year prospective surveillance study","volume":"105","author":"Sharma","year":"2019","journal-title":"Br. J. Ophthalmol."},{"key":"ref_132","first-page":"e485","article-title":"Differences in the prevalence of uveitis between Crohn\u2019s disease and ulcerative colitis: A systematic review and meta-analysis","volume":"102","author":"Lin","year":"2023","journal-title":"Acta Ophthalmol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000353375","article-title":"Managing IBD Outside the Gut: Ocular Manifestations","volume":"31","author":"Calvo","year":"2013","journal-title":"Dig. Dis."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/ICU.0000000000000808","article-title":"A review of ophthalmic manifestations of inflammatory bowel disease and associated treatments","volume":"32","author":"Janardhana","year":"2021","journal-title":"Curr. Opin. Ophthalmol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in Patients with Active Noninfectious Uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"New Engl. J. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/MEG.0000000000002510","article-title":"Outcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel disease","volume":"35","author":"Sayed","year":"2023","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/ibd\/izaa293","article-title":"The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study","volume":"27","author":"Ramos","year":"2020","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1016\/S0140-6736(18)30300-3","article-title":"Primary sclerosing cholangitis","volume":"391","author":"Dyson","year":"2018","journal-title":"Lancet"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/ecco-jcc\/jjz094","article-title":"Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study","volume":"13","author":"Guerra","year":"2019","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.23082","article-title":"High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis #","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1056\/NEJMra1506330","article-title":"Primary Sclerosing Cholangitis","volume":"375","author":"Lazaridis","year":"2016","journal-title":"New Engl. J. Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/12\/4408\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T06:21:12Z","timestamp":1780899672000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/12\/4408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":141,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["jcm15124408"],"URL":"https:\/\/doi.org\/10.3390\/jcm15124408","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,6]]}}}